Acrivon Therapeutics Inc (ACRV) PT Lowered to $27 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Etzer Darout lowered the price target on Acrivon Therapeutics Inc (NASDAQ: ACRV) to $27.00 (from $28.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
